CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)
CervoMed (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, announced an upcoming oral presentation at the 19th International Conference on Alzheimer's and Parkinson's Diseases (AP/PD™) in Vienna, Austria on April 5, 2025.
The presentation will focus on detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB). The presentation will be delivered by CEO John Alam, MD, and Stephen Gomperts, MD, PhD, from Harvard Medical School and Massachusetts General Hospital.
CervoMed (NASDAQ: CRVO), un'azienda in fase clinica che sviluppa trattamenti per i disturbi neurologici legati all'età, ha annunciato una prossima presentazione orale alla 19ª Conferenza Internazionale sulle Malattie di Alzheimer e Parkinson (AP/PD™) a Vienna, Austria, il 5 aprile 2025.
La presentazione si concentrerà su analisi dettagliate della Fase di Estensione dello studio RewinD-LB Fase 2b di neflamapimod nella demenza con corpi di Lewy (DLB). La presentazione sarà tenuta dal CEO John Alam, MD, e da Stephen Gomperts, MD, PhD, della Harvard Medical School e del Massachusetts General Hospital.
CervoMed (NASDAQ: CRVO), una empresa en etapa clínica que desarrolla tratamientos para trastornos neurológicos relacionados con la edad, anunció una próxima presentación oral en la 19ª Conferencia Internacional sobre las Enfermedades de Alzheimer y Parkinson (AP/PD™) en Viena, Austria, el 5 de abril de 2025.
La presentación se centrará en análisis detallados de la Fase de Extensión del estudio RewinD-LB Fase 2b de neflamapimod en demencia con cuerpos de Lewy (DLB). La presentación será realizada por el CEO John Alam, MD, y Stephen Gomperts, MD, PhD, de la Escuela de Medicina de Harvard y del Hospital General de Massachusetts.
CervoMed (NASDAQ: CRVO), 노화 관련 신경 질환 치료제를 개발하는 임상 단계 회사가 2025년 4월 5일 오스트리아 비엔나에서 열리는 제19회 알츠하이머 및 파킨슨병 국제 회의 (AP/PD™)에서 구두 발표를 할 예정이라고 발표했습니다.
이번 발표는 루이체체 치매(DLB)에서 neflamapimod의 RewinD-LB 2b 단계 연구의 연장 단계에 대한 상세 분석에 초점을 맞출 것입니다. 발표는 CEO John Alam, MD와 하버드 의대 및 매사추세츠 종합 병원의 Stephen Gomperts, MD, PhD가 진행합니다.
CervoMed (NASDAQ: CRVO), une entreprise en phase clinique développant des traitements pour les troubles neurologiques liés à l'âge, a annoncé une prochaine présentation orale lors de la 19e Conférence Internationale sur les Maladies d'Alzheimer et de Parkinson (AP/PD™) à Vienne, Autriche, le 5 avril 2025.
La présentation se concentrera sur des analyses détaillées de la phase d'extension de l'
CervoMed (NASDAQ: CRVO), ein Unternehmen in der klinischen Phase, das Behandlungen für altersbedingte neurologische Störungen entwickelt, gab eine bevorstehende mündliche Präsentation auf der 19. Internationalen Konferenz über Alzheimer- und Parkinson-Krankheiten (AP/PD™) in Wien, Österreich, am 5. April 2025 bekannt.
Die Präsentation wird sich auf detaillierte Analysen aus der Erweiterungsphase der RewinD-LB Phase 2b Studie zu neflamapimod bei Demenz mit Lewy-Körpern (DLB) konzentrieren. Die Präsentation wird von CEO John Alam, MD, und Stephen Gomperts, MD, PhD, von der Harvard Medical School und dem Massachusetts General Hospital gehalten.
- None.
- None.
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™), being held on April 1-5, 2025 in in Vienna, Austria. The Company will be presenting detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB).
Details of the AP/PD™ presentation are as follow:
Abstract Title: Efficacy and safety results of the RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)
Format: Oral Presentation
Presenters: John Alam, MD, CEO of CervoMed and Co-Principal Investigator of the RewinD-LB Study and Stephen Gomperts, MD, PhD, Associate Professor of Neurology at Harvard Medical School and Director, Lewy Body Dementia Unit at the Massachusetts General Hospital.
Session Name: Advances in PD, LBD, and MSA Drug Development
Presentation Date and Time: Saturday, April 5th, 2025, 18.25-18.40 pm CET
The abstract will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/ following the presentation.
About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b trial in patients with DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
FAQ
What will CervoMed (CRVO) present at the AP/PD conference in April 2025?
When and where will CervoMed (CRVO) present their RewinD-LB Phase 2b study results?
Who will present the RewinD-LB Phase 2b study results for CervoMed (CRVO)?
Where can investors access CervoMed's (CRVO) AP/PD conference presentation materials?
